What the FDA labels say about taking them together
Amiloride and moexipril
Moexipril's FDA label of January 23, 2026 names amiloride in its drug interactions section; amiloride's label does not name moexipril itself but warns about its class (ACE inhibitors). The moexipril label: “Use of potassium-sparing diuretics or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.”
Check it at the source: the amiloride FDA label on DailyMed (effective May 5, 2023, Padagis US LLC); the moexipril FDA label on DailyMed (effective January 23, 2026, Glenmark Pharmaceuticals Inc., USA).
What does the amiloride label say about moexipril?
Amiloride's label does not name moexipril itself; it warns about its class (ACE inhibitors):
Amiloride label, warningsThe risk of hyperkalemia may be increased when potassium-conserving agents, including amiloride HCl, are administered concomitantly with an angiotensin-converting enzyme inhibitor, an angiotensin II receptor antagonist, cyclosporine or tacrolimus. (See PRECAUTIONS, Drug Interactions .) Warning signs or symptoms of hyperkalemia include paresthesias, muscular weakness, fatigue, flaccid paralysis of the extremities, bradycardia, shock, and ECG abnormalities.
Amiloride label, drug interactionsDrug Interactions When amiloride HCl is administered concomitantly with an angiotensin-converting enzyme inhibitor, an angiotensin II receptor antagonist, cyclosporine or tacrolimus, the risk of hyperkalemia may be increased.
Source: FDA drug label (amiloride hydrochloride), Padagis US LLC, effective May 5, 2023 (SPL set 2b70cf0c-45be-428f-b396-5001ed4e30fc), via openFDA; the full label on DailyMed
What does the moexipril label say about amiloride?
Moexipril label, drug interactionsUse of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.
Source: FDA drug label (Moexipril Hydrochloride), Glenmark Pharmaceuticals Inc., USA, effective January 23, 2026 (SPL set baac91ad-f8ee-4694-89f8-5c47a8eda39a), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Amiloride | Moexipril | |
|---|---|---|
| Labeled for | High blood pressure, Heart failure | n/a |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.190 per tablet 5 mg tablet | $1.00 per tablet 15 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once